Renal Failure Chronic Requiring Hemodialysis Clinical Trial
Official title:
Serum Neutrophil Gelatinase Associated Lipocalin (NGAL) Levels in Hemodialysis (HD) Patients; Relation to Iron Status, Hemodialysis, and Intravenous (IV) Iron Administration
The purpose of this study is to assess changes in serum levels of the siderophore binding protein NGAL by hemodialysis without and with intravenous iron administration
Serum and urine levels of the siderophore binding protein neutrophil gelatinase associated
lipocalin (NGAL) are increased in a number of renal diseases, but has not been evaluated yet
in dialysis patients. Since NGAL is suggested to be related to inflammatory processes and
iron homeostasis, which are a major problem in dialysis patients, this study aims to assess
the relation of serum NGAL levels in hemodialysis (HD) patients to iron status,
inflammation, hemodialysis and intravenous(IV) iron administration. Our hypothesis is that
serum NGAL levels in HD patients are related to iron status and inflammation and may change
following hemodialysis and/or acute or chronic IV iron administration.
The Specific aims are:
1. To assess the relations between basal serum NGAL levels to iron, dialysis, and
inflammation related parameters.
2. To assess the effect of HD on serum NGAL levels and their relation with with iron,
dialysis and inflammation related parameters.
3. To assess the effects of weekly 100 mg IV iron in the first hour of HD on serum NGAL
levels, and the relation of pre IV iron serum NGAL levels with iron, oxidative stress
and inflammation related parameters. These assessments will be performed in the first
weekly HD.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01947673 -
Mechanisms of Intradialytic Hypertension
|
N/A | |
| Not yet recruiting |
NCT03634904 -
Serum Ceftazidime Concentrations in Hemodialysis Patients
|
N/A | |
| Terminated |
NCT01982864 -
Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.
|
Phase 4 | |
| Completed |
NCT01421771 -
Blood Pressure in Dialysis Patients
|
N/A | |
| Completed |
NCT01448174 -
Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
|
Phase 4 | |
| Completed |
NCT01722695 -
Performance Comparison of Revaclear With Larger Dialyzer
|
N/A | |
| Withdrawn |
NCT01015313 -
Effects of Intensified Sodium Management in Hemodialysis Patients
|
N/A | |
| Completed |
NCT02259413 -
Effect of an Exercise Rehabilitation Program on Symptoms in Hemodialysis
|
N/A | |
| Not yet recruiting |
NCT02452788 -
Pharmaceutical Care in Ambulatory Hemodialysis Patients
|
N/A | |
| Recruiting |
NCT01356563 -
Efficacy Study of Pharmacist Intervention on Medication-related Problems in Hemodialysis Patients
|
N/A | |
| Completed |
NCT01320202 -
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
|
Phase 3 | |
| Completed |
NCT01181544 -
A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis
|
N/A | |
| Completed |
NCT02285075 -
Temocillin Pharmacokinetic in Hemodialysis
|
Phase 4 | |
| Completed |
NCT02825589 -
BIA-Guided Dry Weight Assessment on Sleep Quality in Chronic Hemodialysis Patients
|
N/A | |
| Completed |
NCT00890045 -
Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study
|
N/A | |
| Not yet recruiting |
NCT02264964 -
Duration and Adverse Events of Non-cuffed Catheter in Patients With Hemodialysis
|
N/A | |
| Terminated |
NCT01312441 -
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
|
Phase 4 | |
| Completed |
NCT01214928 -
Hemodialysis Vitamin D Pilot
|
N/A | |
| Completed |
NCT00967993 -
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
|
Phase 2 | |
| Completed |
NCT01981603 -
Transplant Navigator Dissemination
|
N/A |